Amgen Inc. (NASDAQ:AMGN) Shares Sold by Northwest Capital Management Inc

Northwest Capital Management Inc trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,936 shares of the medical research company’s stock after selling 66 shares during the quarter. Northwest Capital Management Inc’s holdings in Amgen were worth $765,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Lansing Street Advisors lifted its holdings in shares of Amgen by 1.3% in the 3rd quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company’s stock valued at $832,000 after buying an additional 32 shares during the period. Unionview LLC raised its position in Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company’s stock worth $282,000 after acquiring an additional 32 shares in the last quarter. AM Investment Strategies LLC lifted its holdings in Amgen by 0.4% in the third quarter. AM Investment Strategies LLC now owns 7,471 shares of the medical research company’s stock valued at $2,407,000 after acquiring an additional 33 shares during the period. Avidian Wealth Enterprises LLC boosted its position in shares of Amgen by 0.6% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company’s stock worth $1,889,000 after purchasing an additional 33 shares in the last quarter. Finally, Beacon Financial Advisory LLC grew its stake in shares of Amgen by 4.6% during the 3rd quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company’s stock worth $248,000 after purchasing an additional 34 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on AMGN shares. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Bank of America lifted their price target on shares of Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research report on Thursday, February 6th. UBS Group restated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Leerink Partners reduced their price objective on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $314.09.

Amgen Trading Up 1.7 %

Shares of Amgen stock opened at $303.01 on Monday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The business’s fifty day moving average is $276.27 and its two-hundred day moving average is $300.31. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a market cap of $162.78 billion, a PE ratio of 40.13, a P/E/G ratio of 2.58 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts anticipate that Amgen Inc. will post 20.6 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.14%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insider Activity at Amgen

In other news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the transaction, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at $13,025,590.94. The trade was a 16.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.